These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 23088447)

  • 1. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study.
    Giannini M; Portaccio E; Ghezzi A; Hakiki B; Pastò L; Razzolini L; Piscolla E; De Giglio L; Pozzilli C; Paolicelli D; Trojano M; Marrosu MG; Patti F; La Mantia L; Mancardi G; Solaro C; Totaro R; Tola MR; De Luca G; Lugaresi A; Moiola L; Martinelli V; Comi G; Amato MP
    BMC Neurol; 2012 Oct; 12():124. PubMed ID: 23088447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy and fetal outcomes following paternal exposure to glatiramer acetate.
    Kaplan S; Dragut CF; Ghimpeteanu A
    Curr Med Res Opin; 2024 May; 40(5):821-825. PubMed ID: 38577712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.
    Pecori C; Giannini M; Portaccio E; Ghezzi A; Hakiki B; Pastò L; Razzolini L; Sturchio A; De Giglio L; Pozzilli C; Paolicelli D; Trojano M; Marrosu MG; Patti F; Mancardi GL; Solaro C; Totaro R; Tola MR; De Luca G; Lugaresi A; Moiola L; Martinelli V; Comi G; Amato MP;
    BMC Neurol; 2014 May; 14():114. PubMed ID: 24884599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancy and fetal outcomes following maternal exposure to glatiramer acetate in all three trimesters of pregnancy.
    Kaplan S; Zeygarnik M; Stern T; Hellwig K
    Eur J Neurol; 2023 Dec; 30(12):3890-3895. PubMed ID: 37565380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glatiramer acetate during early pregnancy: A prospective cohort study.
    Herbstritt S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
    Mult Scler; 2016 May; 22(6):810-6. PubMed ID: 26754804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study.
    Weber-Schoendorfer C; Schaefer C
    Mult Scler; 2009 Sep; 15(9):1037-42. PubMed ID: 19692433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
    Lu E; Wang BW; Guimond C; Synnes A; Sadovnick D; Tremlett H
    Neurology; 2012 Sep; 79(11):1130-5. PubMed ID: 22933738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
    Charles JA; Tremlett H; Lu E; Guimond C; Sadovnick AD
    Neurology; 2013 Mar; 80(11):1068-9. PubMed ID: 23479468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes.
    Salminen HJ; Leggett H; Boggild M
    J Neurol; 2010 Dec; 257(12):2020-3. PubMed ID: 20625758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
    Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S
    Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.
    Friend S; Richman S; Bloomgren G; Cristiano LM; Wenten M
    BMC Neurol; 2016 Aug; 16(1):150. PubMed ID: 27552976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).
    Jongen PJ; Hengstman G; Hupperts R; Schrijver H; Gilhuis J; Vliegen JH; Hoogervorst E; van Huizen M; van Munster E; Samijn J; de Schryver E; Siepman T; Tonk M; Zandbergen E; ten Holter J; van der Kruijk R; Borm G
    BMC Neurol; 2011 Mar; 11():40. PubMed ID: 21450086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis.
    Andersen JB; Sellebjerg F; Magyari M
    Eur J Neurol; 2023 Jan; 30(1):162-171. PubMed ID: 36098960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.
    Schippling S; O'Connor P; Knappertz V; Pohl C; Bogumil T; Suarez G; Cook S; Filippi M; Hartung HP; Comi G; Jeffery DR; Kappos L; Goodin DS; Arnason B
    J Neurol; 2016 Jul; 263(7):1418-26. PubMed ID: 27177997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project.
    Lopez-Leon S; Geissbühler Y; Sabidó M; Turkson M; Wahlich C; Morris JK
    J Neurol; 2020 Sep; 267(9):2721-2731. PubMed ID: 32444984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study).
    Fernández Liguori N; Klajn D; Acion L; Cáceres F; Calle A; Carrá A; Cristiano E; Deri N; Garcea O; Jaureguiberry A; Onaha P; Patrucco L; Riccio P; Rotta Escalante R; Saladino Ml; Sinay V; Tarulla A; Villa A
    Mult Scler; 2009 May; 15(5):555-62. PubMed ID: 19299437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and Breastfeeding.
    Kaplan S; Zeygarnik M; Stern T
    Drug Saf; 2022 Apr; 45(4):345-357. PubMed ID: 35297004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.
    Hellwig K; Geissbuehler Y; Sabidó M; Popescu C; Adamo A; Klinger J; Ornoy A; Huppke P;
    J Neurol; 2020 Jun; 267(6):1715-1723. PubMed ID: 32100126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.
    Thiel S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
    Mult Scler; 2016 May; 22(6):801-9. PubMed ID: 26920382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.
    MacDonald SC; McElrath TF; Hernández-Díaz S
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):556-560. PubMed ID: 30834654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.